TAIPEI – October 28, 2026 -- The 2026 Global Health and Welfare Forum brings together 43 speakers and moderators from 11 markets on Oct. 19–20 to test how AI, interoperable health data and precision medicine can move from research into hospitals, pharmaceutical manufacturing, medical-device companies and care networks. The program runs under the theme "The Future of Global Care: Achieving Trust-Centric Digital Health."

FREDERICK, Md. – – October 28, 2026 -- CellectGen has secured Small Business Innovation Research (SBIR) funding to develop a saliva-based, point-of-care diagnostic for periodontal disease, targeting early detection of active tissue destruction. The company is building the platform with reagent supplier Kemp Proteins and lateral-flow developer DCNDx.

BOSTON – October 28, 2026 -- Dechra, a global veterinary specialty care company, reported a 27% cut in Scope 1 and 2 greenhouse gas emissions since its baseline year and R&D spending equal to 9.6% of global revenue in fiscal 2026. The figures come from its 2026 Sustainability Report.

WASHINGTON – October 28, 2026 -- LUNGevity Foundation and the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) have awarded $620,000 to an early-phase clinical trial at The Ohio State University Comprehensive Cancer Center. The trial will test whether pairing two FDA-approved drugs can stop resistance to osimertinib in EGFR-positive non-small cell lung cancer (NSCLC).

BERLIN – October 28, 2026 -- Appian (Nasdaq: APPN) and contract research organisation PSI have taken a live AI-powered process orchestration solution for clinical trial site identification and selection into operation, the first joint project between the two companies.

The solution covers therapeutic areas, indications and geographies. It moves previously manual, decentralised steps into a single digital process, from project initiation through the later stages of site selection.

WASHINGTON – October 28, 2026 -- LUNGevity Foundation and patient advocacy group RETpositive have awarded a combined $340,000 to two research projects targeting drug resistance in RET-positive cancers, where tumors eventually outlast the two FDA-approved RET tyrosine kinase inhibitors (TKIs).

OSLO – – October 28, 2026 -- Photocure ASA raised its 2026 product revenue growth guidance to 10% to 12% on a constant currency basis, up from 8% to 11%, after Hexvix/Cysview revenues of NOK 134.2 million in the third quarter matched the prior-year level of NOK 134.1 million.

NEW YORK – October 28, 2026 -- Breakthrough T1D, the global type 1 diabetes (T1D) research and advocacy organization, has presented four awards to researchers whose work spans disease prevention, insulin pump therapy, beta cell biology and large-scale clinical trials. The recipients were recognized at a ceremony in Philadelphia earlier in October 2026.

Chief Scientific Officer Sanjoy Dutta, Ph.D., said the honorees embody the organization's mission "to accelerate research toward cures for type 1 diabetes while improving the lives of those who live with it."

MILAN – October 28, 2026 -- Bracco Imaging will invest $230 million to build its first U.S. manufacturing facility for injectable contrast media in Sanford, North Carolina, creating an expected 200 jobs.

Plant targets the company's largest market

The United States is Bracco's largest market. The sterile manufacturing site will add U.S. production capacity for injectable contrast media used in diagnostic imaging. Bracco says the added capacity will help it meet growing demand and respond to customer needs.

Edinburgh – October 27, 2026 -- Excelra has taken over the bioinformatics services of Fios Genomics Ltd and the Edinburgh team behind them, effective 20 October 2026. The move adds omics analytics capacity to the scientific informatics company's UK and European operations.

Fios team joins Excelra's scientific consulting group

The Fios scientists become part of Excelra's wider scientific consulting group. They will keep serving existing Fios clients on the same platform, according to the companies. The announcement does not disclose financial terms.